This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merck Names Clark CEO

Updated from 9:53 a.m. EDT

Merck (MRK - Get Report) said Thursday that Raymond V. Gilmartin retired as chairman, chief executive and president, effective immediately, stepping down from the posts about 10 months before he had previously planned.

Although Gilmartin, 64, had been scheduled to retire in March 2006, the timing of his departure was surprising, as was the choice of an insider to succeed him. Many analysts had expected Merck to choose someone outside the company.

The new chief executive and president is Richard T. Clark, 59, who had been president of Merck's manufacturing division. The company won't choose a chairman for at least 12 to 18 months.

The company's stock barely budged on the news, losing 2 cents to $34.91.

Merck's board also announced that Lawrence A. Bossidy, a director, will become chairman of the board's newly constituted executive committee "which will work closely with Mr. Clark to provide support and continuity as he assumes his new duties."

This three-member committee will remain in effect for one to two years. During that period, the board doesn't expect to select a chairman. Bossidy is a former chairman and CEO of Honeywell International (HON - Get Report).

Gilmartin became Merck's CEO in June 1994 after serving as chairman and CEO of the medical device maker Becton Dickinson (BDX). He will remain as a special adviser to the board's executive committee.

Troubles With Vioxx

Gilmartin had come under fire for the company's handling of the withdrawal of the arthritis drug Vioxx, its weak stock performance and the difficulty in replacing older big-selling drugs that are losing patent protection with new drugs that have big revenue prospects.

Even as late as last week at the company's annual meeting, Gilmartin and other Merck officials had said the board would conduct an orderly selection procedure that would have led to a new CEO being chosen by year-end. At the annual meeting, Gilmartin was among eight nominees for the board of directors. He was re-elected with 95% of the votes cast.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
MHS $70.30 0.00%
HON $105.55 1.30%
MRK $58.68 2.00%
AAPL $122.55 -0.67%
FB $96.06 0.80%

Markets

Chart of I:DJI
DOW 17,730.98 +100.71 0.57%
S&P 500 2,102.85 +9.60 0.46%
NASDAQ 5,096.8520 +7.6460 0.15%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs